ValiRx plc (VAL.L) LSE
0.19
-0.005(-2.56%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
0.19
-0.005(-2.56%)
Currency In GBp
Address
Stonebridge House
Hatfield, CM22 7BD
United Kingdom of Great Britain and Northern Ireland (the)
Phone
442030084416
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
January 07, 2002
| Name | Title | Pay | Year Born |
| Mark Eccleston | Chief Executive Officer, Director, Member of Scientific & Commercial Advisory Board | 83,381 | 1971 |
| James Gerry Desler | Chief Financial Officer, Company Secretary & Executive Director | 66,450 | 1945 |
| Kumar Nawani | Head of Operations | 0 | N/A |
| Mark Treharne | Corporate Development Manager | 0 | N/A |
| Andrew Carnegie | Head of Strategic Commercial Development | 0 | N/A |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.